Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-03-04 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release titled 'RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights.' The document length is 2110 characters, which is relatively short and primarily serves as an announcement of the financial results rather than containing the full detailed report itself. The text states that the press release is attached and incorporated by reference, indicating this is an announcement rather than the full annual report or earnings release. According to the 'Menu vs Meal' rule, such short documents announcing the availability of a report should be classified as Regulatory Filings (RNS).
2020-03-04 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It references a press release about an upcoming full-year 2019 financial results conference call. The document is short (2162 characters) and primarily serves as a regulatory filing to report the press release and conference call announcement. It does not contain actual financial statements or detailed financial data. According to the rules, Form 6-K filings that report such announcements without substantive financial data are classified as Regulatory Filings (RNS).
2020-02-27 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It includes a press release about acquiring rights to a product from AstraZeneca. Form 6-K is a periodic report for foreign private issuers to disclose material information. The document is short (2117 characters) and primarily serves as a regulatory filing to report a corporate event. It does not contain financial statements, detailed financial analysis, or management discussion. It is not an annual or interim report, earnings release, or any other detailed financial or governance report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-02-25 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It reports a credit agreement entered into by the company, detailing financing terms, loan tranches, covenants, and related financial arrangements. The document includes a press release about a $115 million non-dilutive financing agreement. The content focuses on financing activities and capital structure updates rather than full financial statements or earnings results. The document length is 9379 characters, which is substantive and contains detailed information about the financing agreement. Therefore, this filing fits the category of Capital/Financing Update (CAP).
2020-02-25 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It includes a press release about a presentation at a healthcare conference. The document is short (2123 characters) and primarily serves as a regulatory filing to report current events or information. It does not contain financial statements or detailed financial analysis, nor does it present a full report such as an annual or interim report. It also does not fit into categories like earnings release, management report, or capital update. Given these characteristics and the nature of Form 6-K filings, the appropriate classification is Regulatory Filings (RNS).
2020-02-18 English
AMENDMENT NO. 3 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-02-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.